1,542 Shares in Thermo Fisher Scientific Inc. (NYSE:TMO) Acquired by Tandem Investment Partners LLC

Tandem Investment Partners LLC acquired a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 1,542 shares of the medical research company’s stock, valued at approximately $802,000.

A number of other hedge funds and other institutional investors have also modified their holdings of TMO. Norges Bank acquired a new position in Thermo Fisher Scientific in the fourth quarter valued at approximately $3,149,754,000. Proficio Capital Partners LLC boosted its holdings in shares of Thermo Fisher Scientific by 68,617.0% in the 4th quarter. Proficio Capital Partners LLC now owns 762,759 shares of the medical research company’s stock valued at $396,810,000 after buying an additional 761,649 shares in the last quarter. Raymond James Financial Inc. purchased a new position in shares of Thermo Fisher Scientific in the 4th quarter valued at $377,901,000. Grantham Mayo Van Otterloo & Co. LLC lifted its position in Thermo Fisher Scientific by 140.7% in the fourth quarter. Grantham Mayo Van Otterloo & Co. LLC now owns 1,093,866 shares of the medical research company’s stock valued at $569,062,000 after acquiring an additional 639,467 shares during the last quarter. Finally, Lindsell Train Ltd purchased a new position in shares of Thermo Fisher Scientific during the fourth quarter worth about $211,858,000. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

TMO has been the subject of a number of research analyst reports. Morgan Stanley upped their target price on Thermo Fisher Scientific from $647.00 to $678.00 and gave the company an “overweight” rating in a research report on Friday, January 31st. UBS Group raised their target price on shares of Thermo Fisher Scientific from $700.00 to $715.00 and gave the stock a “buy” rating in a research report on Friday, January 31st. Raymond James reiterated an “outperform” rating and set a $667.00 price target (up previously from $650.00) on shares of Thermo Fisher Scientific in a research note on Monday, February 3rd. Wells Fargo & Company lifted their price objective on shares of Thermo Fisher Scientific from $660.00 to $680.00 and gave the company an “overweight” rating in a research note on Friday, January 31st. Finally, Scotiabank upped their price objective on Thermo Fisher Scientific from $605.00 to $650.00 and gave the company a “sector perform” rating in a research note on Monday, February 3rd. Four investment analysts have rated the stock with a hold rating and nineteen have given a buy rating to the stock. According to MarketBeat.com, Thermo Fisher Scientific currently has a consensus rating of “Moderate Buy” and a consensus target price of $653.23.

Thermo Fisher Scientific Price Performance

NYSE:TMO opened at $437.80 on Tuesday. The firm has a market cap of $165.16 billion, a price-to-earnings ratio of 26.49, a price-to-earnings-growth ratio of 2.99 and a beta of 0.86. Thermo Fisher Scientific Inc. has a 12-month low of $411.21 and a 12-month high of $627.88. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.59. The company’s 50-day moving average is $529.09 and its two-hundred day moving average is $545.75.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Thursday, January 30th. The medical research company reported $6.10 earnings per share for the quarter, topping analysts’ consensus estimates of $5.94 by $0.16. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. Research analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, April 15th. Shareholders of record on Friday, March 14th will be issued a $0.43 dividend. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.39. The ex-dividend date is Friday, March 14th. This represents a $1.72 annualized dividend and a yield of 0.39%. Thermo Fisher Scientific’s payout ratio is 10.41%.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of the business’s stock in a transaction that occurred on Tuesday, February 4th. The shares were sold at an average price of $585.59, for a total transaction of $175,677.00. Following the completion of the sale, the executive vice president now directly owns 16,363 shares in the company, valued at $9,582,009.17. The trade was a 1.80 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $516.67, for a total value of $5,166,700.00. Following the completion of the sale, the chief executive officer now owns 115,174 shares of the company’s stock, valued at approximately $59,506,950.58. This represents a 7.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 23,900 shares of company stock worth $13,106,062 in the last three months. Company insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.